• About
• Links
• Contact
• Sitemap

Latin American Developing Markets for Pharmaceuticals, 2006-2011

- Is your company profiting from selling to new developing health markets?
- Or are you outsourcing your clinical trials to cheaper developing nations?
- Have you structured licensing agreements for production there?
- What pricing structures should be in place for Latin America?

This report discusses prospects for the large developing market of Latin America. Importantly, the growth of pharmaceutical markets in Latin America has the potential to offset serious problems currently being experienced by your industry. The purpose of this report is to examine the prospects for the growth of pharmaceutical revenues in the developing economies of Latin America, at both regional and national level.

• The growth of pharmaceutical markets in Latin America nations has the potential to offset serious problems currently experienced by the global industry. The principal challenge is slow growth in North America, Western Europe and Japan.
• In contrast, visiongain predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors. 

- Will counterfeit drugs impact on these opportunities? Find out in this exclusive management report.

Latin American Developing Markets for Pharmaceuticals, 2006-2011, examines developing pharmaceutical markets critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Latin American Developing Markets for Pharmaceuticals, 2006-2011, concentrates on the following themes:

• A forecast of the global pharmaceutical market from 2006-2011, with key issues discussed
• Forecasts of sales revenues and growth rates for leading developing markets in Latin America from 2006-2011
• Drivers and opportunities in those markets
• Restraints and threats in those markets
• Discussion of key players and important therapeutic areas
• Discussion of relevant regulatory, societal and economic issues
• Comparison of the prospects for revenue generation in Asia, Latin America and
• Central/Eastern Europe, with overall forecasts for those regions

7 Reasons Why you should buy this report: 

1. To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Latin America from 2006-2011, as well as comparative data for other developing regions
2. To discover predicted revenues, growth rates and other key metrics for Latin American developing markets from 2006-2011
3. To determine the forces that influence pharmaceutical sales in the Latin American developing markets
4. Secure Competitive advantage win the market, both at national and regional level
5. To benefit from the Regulatory, technological, societal and political opportunities in Latin America
6. Understand the critical Drivers and restraints to success in Latin America
7. Harness the Strengths, weaknesses, opportunities and threats your company faces through investment in Latin America

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, companies like yours are very interested in raising their profiles in the developing market of Latin America. Give your company that extra edge by discovering the opportunities today.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets. That situation will provide one of the greatest opportunities currently available to the international pharmaceutical industry. Many developing countries have strongly growing economies; that factor constitutes a driving force in the reform and broadening of healthcare systems. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic products. Private healthcare will undergo similar developments.

Manufacturers of pharmaceuticals are currently working hard to address unmet healthcare needs in developing countries. By doing so, they are making better treatments available to millions of patients and improving the overall performance of their companies.

Table of Contents

• 1. Executive Summary: Developing Markets for Pharmaceuticals, 2006-2011
• 2. The Global Pharmaceutical Industry Faces Significant Challenges – Will Expansion into Developing Markets Prove to Be the Answer?
  • 2.1 The World Pharmaceutical Market Continues to Grow at a Moderate Rate
  • 2.2 The Principal Markets Are the US, Japan and Leading EU Economies - But Leading Developing Nations Are Narrowing the Gap in Pharmaceutical Revenues
  • 2.3 China is the Ninth Largest World Pharmaceutical Market
  • 2.4 North America, Europe and Japan Continue to Dominate the World Pharmaceutical Market, But Sales in the Developing Markets Are Increasing More Rapidly
  • 2.5 High Growth in the Developing Markets
  • 2.6 China is a Most Exciting Prospect for the Pharmaceutical Industry
  • 2.7 Latin America Exhibits Great Promise for Growth of Pharmaceutical Revenues
  • 2.8 WTO Agreements Affect Pharmaceutical Developments In Emerging Markets
  • 2.9 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints
  • 2.10 Pharmaceutical Companies Will Jostle Vigorously for Position in Developing Markets
  • 2.11The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market
  • 2.12 Sales of Generic Products Continue to Encroach Upon the Market for Branded Drugs
  • 2.13 Patent Protection Strategies Form a Cornerstone of Lifecycle Management
  • 2.14 Is Innovation Declining in the Pharmaceutical Industry?
  • 2.15 There Are Strong Forces Acting on Pharmaceutical Pricing In Leading Markets
    • 2.15.1 The US Branded Market Faces Significant Challenges From Generics and Parallel Trade
    • 2.15.2 Mandatory Price Reductions in Europe Continue to Harass the Pharmaceutical Industry
    • 2.15.3 Governmental Price Controls Are an Established Part of the Japanese Pharmaceutical Market
    • 2.15.4 It Is Possible That Mandatory Cost-Controls in Germany Will Serve As A Precedent For Wider Governmental Controlling of Prices
    • 2.15.5 Reducing Efficiencies in R&D Result in Concerns Over Thinning Pipelines
  • 2.16 Maximising the Impact of Product Launches Yields Commercial Advantages
  • 2.17 Strong Branding is Vital - Both in Established and Emerging Markets
  • 2.18 Expansion Into Developing Countries Will Help to Reinvigorate The Pharmaceutical Industry from 2006-2011
• 3. Developing Pharmaceutical Markets in Latin America
  • 3.1 Latin America Will Provide a Very Large and Fast Growing Market for Pharmaceutical Products from 2005 to 2011
  • 3.2 Latin American Pharmaceutical Markets Are Driven By Several Important Factors
  • 3.3 As In Other Developing Regions, Widespread Poverty Remains A Serious Limiting Factor
  • 3.4 Growth in GDP Will Drive Growth in The Latin American Pharmaceutical Markets
  • 3.5 Protection of IP and Other Regulatory Issues Will Remain Prominent in Latin America
    • 3.5.1 Governmental Intervention Will Attempt to Widen Access to Medications
    • 3.5.2 IP Issues Remain Contentious in Parts of Latin America
    • 3.5.3 There are Also Concerns About Safety and Efficacy of Domestic Products
  • 3.6 Significant Challenges Remain for the Public and Private Sectors in The Improvement of Healthcare in Latin America
  • 3.7 The Pharmaceutical Market in Mexico
  • 3.8 The Pharmaceutical Market in Brazil
  • 3.9 The Pharmaceutical Market in Argentina
  • 3.10 The Pharmaceutical Market in Venezuela
  • 3.11 The Pharmaceutical Market in Puerto Rico
  • 3.12 Overview of Developing Pharmaceutical Markets in Latin America
• 4. Conclusions
  • 4.1 China Will Produce the Largest Revenues of All the Developing Pharmaceutical Markets As Well As the Highest Growth Rate
  • 4.2 Overall Growth of the Leading Developing Markets from 2005-2011 Will Be More than Twice that of the Global Pharmaceutical Market
  • 4.3 The Leading Developing Markets Combined Will Generate More Than a Sixth of Global Pharmaceutical Revenues in 2011
  • 4.4 The Main Drivers of Developing Markets Will Be Increasing Prosperity and High Un-met Needs for Modern Treatments
  • 4.5 The Main Restraint to Growth Will Be Continuing Poverty in the Developing World
  
  

List of Tables

Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005

Table 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011

Table 2.3 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2005

Table 2.4 How the Top 10 Markets Compared With The Rest of the World, 2005

Table 2.5 World Pharmaceutical Revenues ($bn) by Region, 2005

Table 2.6 Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005

Table 2.7 Combined Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005

Table 2.8 A SWOT Analysis for Developing Pharmaceutical Markets, 2006-2011

Table 2.9 The 10 Most Populous Countries – 2005 and 2030 Compared

Table 3.1 Revenues ($bn) for Leading Markets in Latin America, 2005-2011

Table 3.2 Pharmaceutical Revenues ($bn) for Mexico, 2005-2011

Table 3.3 Mexico: Fundamental Demographics and Healthcare Economics

Table 3.4 Pharmaceutical Revenues ($bn) for Brazil, 2005-2011

Table 3.5 Brazil: Fundamental Demographics and Healthcare Economics

Table 3.6 Pharmaceutical Revenues ($bn) for Argentina, 2005-2011

Table 3.7 Argentina: Fundamental Demographics and Healthcare Economics

Table 3.8 Pharmaceutical Revenues ($bn) for Venezuela, 2005-2011

Table 3.9 Venezuela: Fundamental Demographics and Healthcare Economics

Table 3.10 Pharmaceutical Revenues ($bn) for Puerto Rico, 2005-2011

Table 3.11 Puerto Rico: Fundamental Demographics and Healthcare Economics

Table 4.1 The Leading Developing Markets Ranked in Order of Potential Revenue Generation ($bn), 2011

Table 4.2 Developing Markets Ranked by Growth Rate (CAGR %), 2005-2011

Table 4.3 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011

Table 4.4 Share (%) of the World Market by Developing Region, 2005-2011

List of Figures

Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005

Figure 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011

Figure 2.3 World Pharmaceutical Revenues ($bn) by Region, 2005

Figure 2.4 World Market Share (%) by Region, 2005

Figure 2.5 Growth Rates (%) from Previous Year by Region, 2005

Figure 2.6 The Increasing Average Cost ($m) of NME Development, 1976-2005

Figure 3.1 Revenues ($bn) for Leading Markets in Latin America, 2005-2011

Figure 3.2 Combined Revenues ($bn) for Leading Markets in Latin America, 2005-2011

Figure 3.3 Growth Rates (% CAGR) for the Latin American Markets, 2005-2011

Figure 3.4 Pharmaceutical Revenues ($bn) for Mexico, 2005-2011

Figure 3.5 World Market Share (%) for Mexico – 2005 and 2011 Compared

Figure 3.6 Pharmaceutical Revenues ($bn) for Brazil, 2005-2011

Figure 3.7 World Market Share (%) for Brazil – 2005 and 2011 Compared

Figure 3.8 Pharmaceutical Revenues ($bn) for Argentina, 2005-2011

Figure 3.9 World Market Share (%) for Argentina – 2005 and 2011 Compared

Figure 3.10 Pharmaceutical Revenues ($bn) for Venezuela, 2005-2011

Figure 3.11 World Market Share (%) for Venezuela – 2005 and 2011 Compared

Figure 3.12 Pharmaceutical Revenues ($bn) for Puerto Rico, 2005-2011

Figure 3.13 World Market Share (%) for Puerto Rico – 2005 and 2011 Compared

Figure 4.1 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011

Figure 4.2 Revenues ($bn) for Leading Markets of Developing Regions Combined, 2005-2011

Figure 4.3 Share (%) of the World Market by Developing Region, 2005-2011

Figure 4.4 Share (%) of the World Market by Developing Regions Combined, 2005-2011

Other users found this report page using the following search terms: latin america pharmaceutical markets america latin pharmaceutical market share pharma sales industry brazil global

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.